AuthorisedTherapeutic exploratory (Phase II)Interventional

Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)

The DELTA-EBV study is exploring a new medicine called Vemlidy (25mg) for people with Epstein-Barr virus (EBV) infection. This is an early-stage study, like a test drive, to mainly check if the medicine is safe and what side effects people might have. It's called a Phase II trial. Researchers will closely monitor participants for any unwanted effects. They will also look at how the medicine changes the amount of virus found in saliva over time. Additionally, they'll examine how the body's immune system, specifically certain cells and antibodies that fight EBV, responds to the treatment. This helps understand if Vemlidy could be a helpful treatment option for EBV in the future.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Helse Bergen HF

Enrolment target

Start

28 May 2026

Epstein-Barr virus infection

What is this study about?

This study, called DELTA-EBV, is a research project focusing on the Epstein-Barr virus (EBV). EBV is a very common virus that many people carry; it's often known for causing glandular fever. For most people, it doesn't cause serious ongoing problems, but for some, it can. There currently aren't many specific treatments for EBV itself, so this research is important for exploring new options.

The main goal of this study is to see how safe a medicine called Vemlidy is when given to people with EBV. Vemlidy is a tablet that you take by mouth. Researchers will be carefully looking for any side effects or unwanted reactions that people might experience while taking this medicine. This is a key first step in understanding if a new treatment can be used safely.

Beyond safety, the study will also look at how Vemlidy affects the EBV in a person's body. They will test saliva samples to see if the amount of virus present changes. They will also examine how the body's natural defense system (the immune system), including special cells and proteins called antibodies, responds to the virus after taking the medicine. All of this information helps scientists understand if Vemlidy could be an effective way to help people manage EBV infection.

Key takeaways

This study explores a potential new treatment for Epstein-Barr virus (EBV).
It focuses on the safety and effects of a medicine called Vemlidy.
Researchers will check for side effects and how the virus changes in saliva.
Only adults aged 18 and over can participate.
Participation involves taking medicine, clinic visits, and various tests.
You can stop participating at any time.

Who may be eligible?

To join this study, you need to be an adult, 18 years old or older. Both men and women can take part.

There might be other specific health requirements or conditions that mean you can or cannot join. The study team will check these carefully with you if you are interested.

It's important to remember that not everyone who is interested will be able to join, as studies often have strict rules to make sure the results are clear and reliable.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have an Epstein-Barr virus (EBV) infection?
Are you willing to take study medicine regularly?
Are you able to attend clinic visits for tests and check-ups?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would be taking a medicine called Vemlidy, which are tablets, as instructed by the study team. You would have several visits to the study clinic or hospital. During these visits, the team would carry out different assessments. These would likely include physical check-ups, taking blood samples, and collecting saliva samples to measure the virus and your body's response. They would also regularly ask you about your well-being and any side effects you might be experiencing.

The study would involve a period of taking the medicine and then follow-up observations to see how your body continues to respond. The exact number of visits, tests, and the total length of time you would be involved will be explained in detail by the study team.

Potential risks and benefits

Taking part in a study like this might have some benefits, though these are not guaranteed. You would receive close medical attention and contributing to medical knowledge that could help others in the future. However, there are also potential risks. The medicine Vemlidy might cause side effects, some of which could be unknown at this stage. The procedures, such as blood tests, also carry small risks like bruising. All potential risks will be thoroughly explained to you before you decide. Remember, you can choose to leave the study at any time, for any reason, without it affecting your usual care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Norway

Common questions

What is Epstein-Barr virus (EBV)?

EBV is a very common virus, often known for causing glandular fever. Many people carry the virus without symptoms.

What is Vemlidy?

Vemlidy is a medicine taken as a tablet that the researchers are testing to see if it helps with EBV infection.

Why is this study being done?

The study aims to see if Vemlidy is safe and how it affects EBV in people, as there aren't many specific treatments for EBV right now.

Will I get better if I join this study?

This is an early-stage study, so we don't know if the medicine will make you feel better. The main goal is to understand its safety and effects.

What is 'Phase II'?

Phase II means this is an early stage of testing a new medicine. It means researchers are looking mainly at safety and initial effects, rather than how well it fully cures a condition.